Alumis Inc.
ALMS
Classificação em ações
#10397
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Preço da ação
$6.15
Última sincronização: 2026-10-16
Valor de mercado
$795.38M
Variação (1 dia)
-2.61%
Variação (1 ano)
170.70%
País
US
Negociar Alumis Inc. (ALMS)
Categoria
Healthcare
EPS de Alumis Inc. (ALMS)
EPS em March 2025 TTM: $-2.70
De acordo com os últimos relatórios financeiros e o preço das ações da Alumis Inc., o EPS atual da empresa (TTM) é $-2.70. No final de 2023, a empresa teve um EPS de $-5.43, um aumento em relação a ao EPS de 2022, que foi de $-0.70.
Histórico de EPS da Alumis Inc. de 2021 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
